Skip to content
Keressen, hogy többet megtudjon az InterSystems termékeiről és megoldásairól, karrierlehetőségekről és még sok másról. Az eredmények az mellett fejlesztői közösségünk, termékdokumentációink és oktatási webhelyeink tartalmát is tartalmazzák.

How Life Sciences Organizations Can Solve the Data Problem

strand of DNA appearing to glow over a dark blue background

Have you ever bumped into the same obstacle—maybe a sharp edge or a rise in the floor—over and over again? That’s precisely what life sciences organizations have done for years when it comes to how they use data. But instead of walking away with a stubbed toe or a headache, this persistent challenge forces pharmaceutical companies to burn more time and resources to get drugs to market. Patients, meanwhile, miss out on potentially life-saving treatments.

Take it from Matthew Stannard, life sciences advisor to InterSystems. After 20 years in all corners of the life sciences space, he understands the challenges and opportunities facing drug makers. This week on Healthy Data, a podcast series by InterSystems, we speak with Matt to learn more about how life sciences organizations can leverage data, analytics, and artificial intelligence to improve their operations.

Here are a few key points from the conversation.

  • Clinical trials are facing a classic case of “two ships passing in the night.” Life sciences stakeholders can’t find participants to meet enrollment goals, even as they overlook patients who need the drug in question.
  • Disparate data silos are, at least in part, to blame. Access to data from many electronic health records, retrospectively and in real time, and real-world evidence can help solve life sciences’ data challenges.
  • The benefits of embracing data and technology are clear: Patients survive, and life sciences companies thrive. It’s all thanks to access and efficiency.

And COVID-19 has only exacerbated efforts to connect patients with clinical trials, Matt notes. The pandemic has disrupted operations within hospitals and life sciences organizations, leaving a major backlog that threatens further delays for critical drugs.

If the need for life sciences to get creative with data was urgent before, it’s essential now. But the good news is that despite decades of data hardship, drug manufacturers have the ability to embrace tools that could usher in a new age of life sciences innovation.

Take the first step on that journey with Matt and us today on Healthy Data.

About the Hosts / Authors

Jack Murtha, digital storyteller

Jack Murtha is a digital storyteller who specializes in the intersection of healthcare and technology. Connect with Jack on Twitter.



Amid relentless hype, Tom Castles is drawn to those who take relentless action. For more than a decade, he has made a living helping action-oriented people and institutions craft their stories and build strategies that position them to earn the attention they deserve—all in the name of progress toward a more equitable world. Want to catch up? Connect with Tom on Twitter.

Más Hozzászólások, Amiket Szerethet

Revenue cycle management has come a long way, thanks to the integration of data interoperability solutions with electronic health record systems.
The COVID-19 widened the digital divide in healthcare, marked by a rapid shift toward telehealth services. How do we bridge the gap in accessibility?
Senior Advisor for Value-Based Markets
The evolution of healthcare management has accelerated rapidly as the technologies available to practitioners and patients multiply — how do we keep up?
Global Head of Healthcare Market Strategy
Why It Pays to Immerse Yourself in the Great Digital Health Experiment
Co-founder, Map Change
Today we are at a new inflection point in medical history, and it could be argued that this is a time of more pervasive disruption than almost any other.
Vice President, Healthcare
Integration of the FHIR standard is helping developers build the applications, tools, and technologies to facilitate collaborative care.
Head of Developer Relations, Data Platforms
Lynda Rowe of InterSystems discusses the impact of an enterprise master patient index in promoting more precise patient matching and healthcare data interoperability.
Senior Advisor for Value-Based Markets
As we design the healthcare analytics architecture of the future, we need pursue a design that overcomes the limits of information silos, harmonizes all our information assets, and makes them just as accessible as our distributed data, without the blurred vision.
Global Head of Healthcare Market Strategy
I would suggest that the key to using healthcare information technology to address the challenges of virtual and integrated care, is the ability to innovate and push past the possible while also keeping your core business running. This is a concept that Gartner has called “Bimodal IT.”